Phase 1 Pancreatic Cancer Trial, Recruiting NCT06673017 Sponsor: PanTher Therapeutics Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 1 Pancreatic Cancer Trial, Recruiting

NCT06673017
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Imaging results that suggest borderline resectable or locally advanced pancreatic ductal adenocarcinoma (a type of pancreatic cancer), confirmed or to be confirmed through tissue or cell samples
  • A doctor has determined that a laparoscopy (a procedure to look inside the abdomen) is appropriate
  • No previous treatment of any kind for this pancreatic cancer
  • Blood and lab test results that fall within acceptable ranges
  • A general health and functioning level rated 0–2 on a standard medical scale, meaning the person is able to carry out at least some daily activities (confirm with trial site)
  • Able to understand and agree to participation in the trial
  • Not currently experiencing active pancreatitis (painful inflammation of the pancreas)
  • No other active health conditions that would interfere with monitoring the trial's safety or results, or prevent participation
  • People who could become pregnant must agree to use adequate contraception throughout the trial

Who may not be able to join:

  • People with an active non-pancreatic cancer that currently requires treatment, or who have been diagnosed with another cancer within the past 2 years (some exceptions may apply, such as certain low-risk or previously treated cancers — confirm with trial site)
  • People with known allergies or medical reasons preventing the use of the study drug or the chemotherapy medicines used in this trial
  • People with a known history of HIV or currently active hepatitis (a liver infection caused by a virus)
  • People with an active infection or immune system condition that could make laparoscopy, drug placement, chemotherapy, or surgery unsafe
  • People who would be unable to follow the activities and appointments required by the trial
  • People currently enrolled in another clinical trial involving an experimental drug or device
  • People who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the trial; men who plan to donate sperm or father a child during the trial
  • People with other medical or surgical conditions, including previous abdominal surgery, that a doctor determines would make the laparoscopy or implantation procedure unsafe

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 2032419779

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
PanTher Therapeutics
Registry
ClinicalTrials.gov
Start date
14 April 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Dose Escalation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov